Skip to cookie consent Skip to main content
Preview lacks audio; Link to full video with audio follows

Advancing Cancer Discovery and Innovation

Ranked #1 in hospital medical research in the U.S. according to the National Institutes of Health, we are transforming cancer care, driving innovation, and improving patient outcomes with more effective diagnostics, therapeutics, procedures, and technology.

Cancer breakthroughs that are pushing the boundaries

We have always been and continue to be at the forefront in the development and utilization of the latest and most advanced cancer treatments and technologies.

Cancer blood test detects remaining cancer after surgery

Learn more about the blood test Mass General Brigham researchers helped to develop to detect remaining cancer cells after surgery.

Read the Q&A
Aparna Parikh, MD and Ryan Corcoran, MD, PhD in lab

Artificial intelligence drives new approaches to cancer care

Mass General Brigham is leading the way in AI-driven cancer care through innovative projects powered by large language models.

AI in cancer care
Kerry Reynolds, MD with patient.

Leaders and experts in proton therapy

Mass General Brigham is home to the only proton therapy site in New England and was one of the first institutions to use this innovative technology to treat cancer.

Our expertise
Helen Shih, MD with a patient in the proton therapy center

Personalizing head and neck skin cancer treatments with AI

Physician-scientist Kevin Emerick, MD, and principal investigator, Sophia Shalhout, PhD, are collaborating to use AI to customize cancer treatments for head and neck non-melanoma skin cancers.

Read the Q&A
Kevin S. Emerick, M, and Sophia Z. Shalhout, PhD

Minimally invasive robotic surgery

Discover how robotic surgery is transforming cancer care and improving patient recovery with Brigham and Women’s Hospital surgeons, Jiping Wang, MD, PhD, and Timothy Clinton, MD.

Watch video
Surgeon performing robotic surgery at Mass General Brigham.

Using fluorescence lifetime imaging to distinguish tumors from normal tissue

Researcher Anand T. N. Kumar, PhD, discovered how to use fluorescence lifetime imaging to distinguish tumor cells from normal tissue. Learn how his research could transform cancer surgery.

Read the Q&A
Anand Kumar lab
  • Peter Quagge performs a 265-pound deadlift

    Peter's story: Surgical team delivers lifesaving outcome for local athlete

     

    After a diagnosis and treatment of a rare ampullary cancer, Peter, CrossFit athlete and coach, is back competing at a high level.

     

    Read Peter’s story

  • Lindsay Strauss holding the notebook she brought with her to all of her appointments

    Lindsay's story: Proton therapy to treat brain tumor

     

    Expectant mom, Lindsay, suffered a grand mal seizure at 33 weeks pregnant, and was subsequently diagnosed with a brain tumor. Lindsay’s care team created a treatment plan, including proton therapy, that would leave her and her baby healthy.

     

    Read Lindsay’s story

  • Michael King with wife Julia and their son, Cole

    Michael's story: Father with rare cancer gets a second chance

     

    For Michael, who was diagnosed with a gastrointestinal stromal tumor, a minimally invasive procedure that uses robotic precision to remove tumors made all the difference.

     

    Read Michael’s story

The visionary future of CAR T-cell therapy

Our clinician-researchers discuss the power and evolution of immune therapies, specifically, CAR T-cell therapy in treating cancer, and one patient tells the story of his diagnosis and life-changing experience in a clinical trial.

Watch CAR T video
CAR T-cell lab

Treating liver cancer using hepatic arterial infusion pumps

In cases of liver metastases originating from colorectal cancers, patients presenting with unresectable tumors may have limited treatment options. Hepatic arterial infusion pump (HAIP) therapy offers an effective treatment option.

Discover HAIP therapy
Hepatic pump surgery team at Mass General

Revolutionizing immunotherapy

While immunotherapy has altered the landscape of metastatic melanoma, a team of researchers and physician-investigators intends to find answers for patients whose cancers fail to respond to this transformative therapy.

Personalizing immunotherapy
Moshe Sade-Feldman, PhD, Russell Jenkins, MD, PhD, and Genevieve M. Boland, MD, PhD